14 completed, 3 recruiting. 9 Phase 2, 7 Phase 3, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Recruiting 1 |
| Phase 3 | 7 | Completed 5, Recruiting 2 |
| Phase 1 | 6 | Completed 6 |
Follow Trevi Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets NAL ER, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Recruiting | Trevi Therapeutics | 201 | 2026-09-30 | 2026-10-09 |
| Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets NAL ER, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Recruiting | Trevi Therapeutics | 306 | 2026-06-29 | 2026-10-13 |
| The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) NAL ER, Placebo - Refractory Chronic Cough | Phase 2 | Recruiting | Trevi Therapeutics | 100 | 2026-06-22 | 2026-10-13 |
| A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants NAL ER - Healthy Participants | Phase 1 | Completed | Trevi Therapeutics | 60 | 2026-02-27 | 2026-08-21 |
| NAL ER IPF Respiratory Function and Safety Study NAL ER, Placebo - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Trevi Therapeutics | 9 | 2025-08-21 | 2026-08-03 |
| A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants NAL ER, Pirfenidone, Nintedanib - Healthy Participants | Phase 1 | Completed | Trevi Therapeutics | 132 | 2025-06-30 | 2025-10-10 |
| Cough Reduction in IPF With Nalbuphine ER NAL ER, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Trevi Therapeutics | 165 | 2024-02-06 | 2026-06-26 |
| Refractory Chronic Cough Improvement Via NAL ER (RIVER) NAL ER, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Trevi Therapeutics | 66 | 2023-11-30 | 2026-03-30 |
| A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough NAL ER, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Trevi Therapeutics | 42 | 2019-10-29 | 2025-05-29 |
| Study of Nalbuphine ER in Participants With Hepatic Impairment Nalbuphine ER - Hepatic Impairment | Phase 1 | Completed | Trevi Therapeutics | 28 | 2019-06-12 | 2026-03-19 |
| PRISM Study-Pruritus Relief Through Itch Scratch Modulation Nalbuphine ER Tablets, Placebo Tablets - Prurigo Nodularis | Phase 2 / Phase 3 | Completed | Trevi Therapeutics | 353 | 2018-08-07 | 2025-06-24 |
| Oral Abuse Potential Study of Nalbuphine Nalbuphine HCl solution, Placebo solution - Nalbuphine, Opioid Abuse | Phase 1 | Completed | Trevi Therapeutics | 56 | 2018-05-29 | 2025-05-21 |
| Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis nalbuphine HCl ER - Prurigo Nodularis, Nodularis Prurigo | Phase 2 / Phase 3 | Completed | Trevi Therapeutics | 36 | 2015-08-15 | 2025-05-21 |
| Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID, Placebo tablets BID - Prurigo Nodularis, Nodularis Prurigo | Phase 2 / Phase 3 | Completed | Trevi Therapeutics | 62 | 2015-03-01 | 2025-05-21 |
| Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus nalbuphine HCl ER - Uremic Pruritus, Pruritus | Phase 2 / Phase 3 | Completed | Trevi Therapeutics | 167 | 2014-09-01 | 2025-05-21 |
| Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus nalbuphine HCl ER tablets 60 mg BID, nalbuphine HCl ER tablets 120mg BID, Placebo tablets BID - Uremic Pruritus, Pruritus | Phase 2 / Phase 3 | Completed | Trevi Therapeutics | 373 | 2014-06-01 | 2025-05-21 |
| Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus Nalbuphine HCL ER - Uremic Pruritus | Phase 1 | Completed | Trevi Therapeutics | 22 | 2013-04-01 | 2025-05-22 |
Idiopathic Pulmonary Fibrosis (5) · Pruritus (4) · Cough (3) · Chronic Cough (2) · Prurigo (2) · Opioid-Related Disorders (1)
Nalbuphine (11) · BID protein, human (2) · Sugars (2) · nintedanib (1) · pirfenidone (1)
United States (10) · Canada (4) · Germany (4) · Poland (4) · United Kingdom (4) · Australia (1) · Austria (1) · Chile (1) · France (1) · Italy (1) · Netherlands (1) · Romania (1) · Spain (1) · Turkey (Türkiye) (1)
Thomas Sciascia (1)
PMID 36680419, PMID 33283264, PMID 34780095, PMID 34908192, PMID 38320144, PMID 41569557
2018 (2)